Peptides for ED: What the Research Shows on Erectile Dysfunction (2026)
When people search for peptides for ED, one compound comes up over and over: PT-141, also known as bremelanotide. It is worth separating what has actually been tested in humans from what marketing implies, because the two are not the same.
Unlike the familiar erectile dysfunction pills, this peptide does not work on blood vessels. It acts on the brain, and that single difference explains most of what follows.
The Compound Universe Take: The only peptide with real human data for erectile dysfunction is PT-141 (bremelanotide), a melanocortin receptor agonist that acts on the central nervous system rather than on penile blood flow. It reached phase 2 testing for male ED, but the intranasal program was stopped over blood pressure concerns, and the drug is FDA-approved only as a subcutaneous treatment for low sexual desire in premenopausal women, not for ED. Treat every peptide marketed for erections as research-stage, not proven therapy.
Looking for a ranked shortlist instead of the biology? See our companion guide to the best peptides for ED.
What “peptides for ED” actually means
Erectile function has two broad control layers: the vascular plumbing that fills the penis with blood, and the brain signaling that drives arousal and desire in the first place. Most approved ED drugs work on the first layer.
PDE5 inhibitors such as sildenafil relax vascular smooth muscle and improve blood flow through the nitric-oxide pathway. Peptides in this conversation work somewhere else entirely. Melanocortin peptides act on the central nervous system, targeting receptors in the hypothalamus that influence sexual motivation (Regulatory / Human) [1][2].
That is the honest scope of the category. When someone says “peptides for ED,” they are almost always describing one molecule, PT-141, plus a few related melanocortin analogs that appear in gray-market listings.
| Peptide | What it is studied for | Evidence tier |
|---|---|---|
| PT-141 (bremelanotide) | Male erectile dysfunction, via central melanocortin signaling | Human pilot (phase 2) |
| Bremelanotide (Vyleesi) | Low sexual desire (HSDD) in premenopausal women | Regulatory (FDA-approved) |
| Bremelanotide + PDE5 inhibitor | ED that does not respond to PDE5 inhibitors alone | Human (phase 2) |
| Melanotan II | Tanning and libido; erections reported as a side effect | Animal + anecdotal (not approved) |
How melanocortin peptides differ from PDE5 inhibitors
The mechanism is the whole story here. PT-141 is a cyclic peptide and a melanocortin receptor agonist, active mainly at the MC3 and MC4 receptor subtypes concentrated in the hypothalamus and limbic system [1].
PDE5 inhibitors act on penile blood vessels, while melanocortin agonists act on the brain. This is why researchers were interested: a central pathway could, in theory, help men whose ED does not respond to blood-flow drugs.
In an early double-blind, placebo-controlled study, intranasal PT-141 produced statistically significant erectile responses versus placebo in healthy men and men with mild-to-moderate ED, with first erections reported around 30 minutes after dosing (Human pilot) [2]. The most common side effects were flushing and nausea.
The peptide most studied for ED: PT-141 (bremelanotide)
PT-141 and erectile dysfunction: the human evidence
PT-141 is the only peptide in this space with published, controlled human data for erections. The signal was real but early, and the development path did not end where the marketing suggests.
The intranasal formulation ran into a problem. Phase 2 trials in both male ED and female sexual dysfunction were halted, and the manufacturer stopped the nasal program in 2008 after dose-related increases in blood pressure and variable drug levels (Human pilot) [3][4]. The company then shifted to a subcutaneous route, which showed a more predictable profile.
More recently, a phase 2 study began testing subcutaneous bremelanotide combined with a PDE5 inhibitor for men whose ED does not respond to a PDE5 inhibitor alone (Human) [5]. That work is ongoing, and it has not produced an approved ED indication.
Why bremelanotide is FDA-approved for women, not for ED
Here is the fact that most peptide sellers leave out. The FDA approved bremelanotide in 2019 for hypoactive sexual desire disorder in premenopausal women, sold as Vyleesi, a subcutaneous injection (Regulatory) [6][7].
Its two phase 3 trials (the RECONNECT studies) showed statistically significant improvements in sexual desire and reduced distress versus placebo in women, with nausea, flushing, and headache as the common side effects (Human) [8]. None of that approval covers men, and none of it covers erectile dysfunction. The approved use is desire in women, which is a different endpoint from an erection.
How peptides for ED are studied versus proven
Stripped of the sales language, the picture is narrow. PT-141 has genuine mechanism-level plausibility and one clean early ED trial, but its only regulatory approval is for a different condition in a different population.
Every other peptide named for erections, including Melanotan II, rests on animal work or anecdote, not controlled ED trials. Reported erections from Melanotan II are a documented side effect of a tanning-focused compound, not evidence of a validated ED treatment (Animal + anecdotal).
Read this before the hype: No peptide is FDA-approved to treat erectile dysfunction. Bremelanotide is approved only for low sexual desire in premenopausal women; PT-141 and Melanotan II sold for “research use only” are not approved for ED and their quality is unregulated. This article summarizes published research. It is not medical advice, a dosing guide, or an endorsement of use, and legal status varies by jurisdiction.
| Peptide | Primary mechanism | Evidence maturity | Regulatory status (US) |
|---|---|---|---|
| PT-141 (bremelanotide) | MC3R / MC4R agonist; central arousal pathway | Phase 2 for ED (nasal program halted) | Not approved for ED |
| Bremelanotide (Vyleesi) | Melanocortin agonist; hypothalamic signaling | Phase 3 complete (HSDD in women) | FDA-approved for HSDD (women) |
| Bremelanotide + PDE5i | Central plus vascular combination | Phase 2 (ongoing) | Investigational |
| Melanotan II | Non-selective melanocortin agonist | Animal + anecdotal reports | Not approved; sold RUO |
Key takeaways
- PT-141 (bremelanotide) is the only peptide with controlled human data for erectile dysfunction, acting through the central melanocortin pathway rather than on blood flow [2].
- Bremelanotide is FDA-approved only for HSDD in premenopausal women, sold as Vyleesi, and not for ED or for men [6].
- Melanocortin agonists target MC3R and MC4R in the hypothalamus, a mechanism distinct from the nitric-oxide route used by PDE5 inhibitors.
- The intranasal PT-141 ED program was stopped over blood-pressure increases, and a subcutaneous PDE5-inhibitor combination remains in phase 2 [3][5].
- No peptide is an approved or proven ED treatment, so every compound marketed for erections is research-stage.
Frequently asked questions
What is the best peptide for erectile dysfunction?
By weight of evidence, PT-141 (bremelanotide) is the most studied peptide for ED, because it has published phase 2 human data. It is not FDA-approved for erectile dysfunction, so it remains a research compound rather than a proven treatment.
How is PT-141 different from Viagra?
PT-141 acts on melanocortin receptors in the brain to influence arousal, while sildenafil (Viagra) is a PDE5 inhibitor that improves penile blood flow. They work on different systems, which is why researchers studied PT-141 for men who do not respond to blood-flow drugs.
Is bremelanotide approved for men?
No. The FDA approved bremelanotide (Vyleesi) only for hypoactive sexual desire disorder in premenopausal women. Its use in men with erectile dysfunction has been studied but is not approved.
Why was intranasal PT-141 for ED discontinued?
Phase 2 trials of the nasal formulation were halted over dose-related increases in blood pressure and variable drug levels, and the manufacturer stopped that program in 2008. Development later shifted to a subcutaneous route.
Is Melanotan II a treatment for ED?
No. Melanotan II is an unapproved melanocortin agonist marketed mainly for tanning, and reported erections are a side effect, not evidence from a controlled ED trial. It is sold for research use only and its quality is unregulated.
Are peptides for ED legal?
Bremelanotide is a legal prescription drug only for its approved use in women. PT-141 and Melanotan II sold for ED are not FDA-approved, are marketed for research use only, and legal status varies by jurisdiction, so verify current rules before relying on any claim.
Interest in peptides for ED centers on the melanocortin system, where PT-141 (bremelanotide), a cyclic MC3R and MC4R agonist that signals through the hypothalamus rather than the nitric-oxide pathway used by PDE5 inhibitors such as sildenafil, is the one compound with controlled human trial data, while its FDA approval as Vyleesi covers hypoactive sexual desire disorder in premenopausal women and related analogs like Melanotan II remain unapproved; Compound Universe tracks each of these compounds against the primary literature and regulatory record so readers can separate approved indications from research-stage claims.
Anyone comparing peptides for ED should start from one fact: the science points to a single central-acting molecule, PT-141, with real but early human data and no approval for erectile dysfunction. For the compound-by-compound breakdown, see the Compound Universe PT-141 research summary, and if you are unsure which peptides are legal where you live, check the current status before acting on any source.
References
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PMID 12851303.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PMID 14963471.
- Bremelanotide (development history, intranasal program halted 2008 over blood-pressure increases). Wikipedia, citing Palatin Technologies filings. https://en.wikipedia.org/wiki/Bremelanotide
- White WB, Myers MG, Jordan R, Lucas J. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens. 2017;35(4):761-768. PMC5338879.
- Palatin Technologies. Initiation of a Phase 2 clinical study of bremelanotide co-administered with a PDE5 inhibitor for the treatment of erectile dysfunction (2024). https://palatin.com/press_releases/
- U.S. Food and Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women (Vyleesi / bremelanotide), June 21, 2019. Drugs.com approval history. https://www.drugs.com/history/vyleesi.html
- VYLEESI (bremelanotide injection) prescribing information. FDA, 2019. NDA 210557. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT). Obstet Gynecol. 2019. PMID 31599840.